Based on the promising findings presented here, we are currently conducting in vivo studies to evaluate the therapeutic efficacy of the PD-H and FAKi VS-4718 combination in a pancreatic cancer model. The gene discussed is PDP1; the disease is familial pancreatic carcinoma.